ATE328283T1 - Screeningverfahren und verbindungen zur behandlung von friedreich ataxia - Google Patents

Screeningverfahren und verbindungen zur behandlung von friedreich ataxia

Info

Publication number
ATE328283T1
ATE328283T1 AT02014542T AT02014542T ATE328283T1 AT E328283 T1 ATE328283 T1 AT E328283T1 AT 02014542 T AT02014542 T AT 02014542T AT 02014542 T AT02014542 T AT 02014542T AT E328283 T1 ATE328283 T1 AT E328283T1
Authority
AT
Austria
Prior art keywords
treatment
friedreich ataxia
compounds
screening methods
relates
Prior art date
Application number
AT02014542T
Other languages
English (en)
Inventor
Thomas Meier
Matthias Jauslin
Fabrice Schoumacher
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Application granted granted Critical
Publication of ATE328283T1 publication Critical patent/ATE328283T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrrole Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
AT02014542T 2002-07-01 2002-07-01 Screeningverfahren und verbindungen zur behandlung von friedreich ataxia ATE328283T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02014542A EP1378753B1 (de) 2002-07-01 2002-07-01 Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia

Publications (1)

Publication Number Publication Date
ATE328283T1 true ATE328283T1 (de) 2006-06-15

Family

ID=29719694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02014542T ATE328283T1 (de) 2002-07-01 2002-07-01 Screeningverfahren und verbindungen zur behandlung von friedreich ataxia

Country Status (6)

Country Link
US (1) US20050222218A1 (de)
EP (1) EP1378753B1 (de)
AT (1) ATE328283T1 (de)
CA (1) CA2489294A1 (de)
DE (1) DE60211875T2 (de)
WO (1) WO2004003565A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500929B1 (de) * 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
PL1888059T3 (pl) 2005-06-01 2015-06-30 Bioelectron Tech Corp Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych
WO2007015536A1 (ja) * 2005-08-03 2007-02-08 Sumitomo Chemical Company, Limited 化合物、光電変換素子及び光電気化学電池
WO2007035496A1 (en) 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP1951656B1 (de) * 2005-11-11 2015-08-05 The Scripps Research Institute Inhibitoren der histondeacetylase als therapeutika für neurologische erkrankungen
WO2007085036A1 (en) * 2006-01-26 2007-08-02 Medizinische Universität Wien Treatment of friedreich' s ataxia
EP2332534B1 (de) 2006-02-22 2018-11-14 Bioelectron Technology Corporation Phenol- und Benzoquinonederivate zur Verwendung in der Behandlung von Mitochondriopathien und zur Modulation von Energie-Biomarkern
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP1891946A1 (de) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Transmukosale Verabreichung von 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinon
DE102006058183A1 (de) 2006-11-29 2008-06-05 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von Substanzen, die den zellulären Glutathion-Gehalt absenken, zur Herstellung eines Arzneimittels zur Behandlung von T-Zell vermittelten Autoimmunkrankheiten
EP2220030B1 (de) 2007-11-06 2016-01-13 Edison Pharmaceuticals, Inc. 4-(p-chinonyl)-2-hydroxybutanamidderivate zur behandlung von mitochondrialen krankheiten
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2009143019A2 (en) * 2008-05-23 2009-11-26 University Of South Florida Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity
WO2009158348A1 (en) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
MX2011002318A (es) 2008-09-10 2011-05-10 Edison Pharmaceuticals Inc Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
US20110269246A1 (en) * 2009-01-14 2011-11-03 Devin Oglesbee Measuring levels of frataxin
EP2424495B1 (de) 2009-04-28 2018-01-17 Bioelectron Technology Corporation Behandlung von erblicher leber-optikus-neuropathie und dominanter optikus-neuropathie mit tocotrienol-chinonen
JP2012525397A (ja) * 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド 眼科疾患を治療するためのトコトリエノールキノンの製剤
WO2011082355A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
CA2809747C (en) 2010-08-30 2018-05-01 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
US10058612B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
CA2865316A1 (en) * 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
JP6728520B2 (ja) 2011-07-06 2020-07-22 ピーティーシー セラピューティクス， インコーポレイテッド メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置
JP6393684B2 (ja) 2012-09-07 2018-09-19 バイオエレクトロン テクノロジー コーポレイション 個体のレドックス状態の調節において使用するためのキノン誘導体
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
EP3004071A1 (de) 2013-05-31 2016-04-13 Edison Pharmaceuticals, Inc. Carboxylderivate zur behandlung von erkrankungen in verbindung mit oxidativem stress
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
PT3233786T (pt) 2014-12-16 2022-05-06 Ptc Therapeutics Inc Formas polimórficas e amorfas de (r)-2-hidroxi-2-metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
EP3866772B1 (de) 2018-10-17 2023-10-11 PTC Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-dien-1,4-dion zur unterdrückung und behandlung von alpha-synucleinopathien, tauopathien und anderen erkrankungen
WO2021077034A1 (en) 2019-10-18 2021-04-22 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders
EP4351545A1 (de) 2021-06-07 2024-04-17 Katholieke Universiteit Leuven Idebenon zur behandlung von arzneimittelresistenter epilepsie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128365A (en) * 1989-07-19 1992-07-07 The Trustees Of Columbia University In The City Of New York Compounds having glutathione peroxidase activity and use thereof
US6133322A (en) * 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload

Also Published As

Publication number Publication date
EP1378753A1 (de) 2004-01-07
DE60211875T2 (de) 2006-10-26
WO2004003565A2 (en) 2004-01-08
WO2004003565A3 (en) 2004-10-14
CA2489294A1 (en) 2004-01-08
EP1378753B1 (de) 2006-05-31
DE60211875D1 (de) 2006-07-06
US20050222218A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
ATE328283T1 (de) Screeningverfahren und verbindungen zur behandlung von friedreich ataxia
DE60323155D1 (de) Von transthyretin und zur hemmung von transthyretin-fehlfaltung
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DK2075007T3 (da) Behandling af Alzheimers sygdom
CY1111130T1 (el) Αναστολεις κυστεϊνοπρωτεασης κατηγοριας καθεψινης
ATE530560T1 (de) Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
DE602004029680D1 (de) Isoformen von gehirn-natriuretischem peptid
ATE386104T1 (de) Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
DE602005027322D1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
HK1099810A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
DE60026150D1 (de) Diagnostika und therapeutika für osteoporose
DK1408976T5 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
DE60126248D1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
DE60313424D1 (de) Methode und System für eine automatisierte Dokumentverarbeitung
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE520987T1 (de) Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum
ATE414736T1 (de) Verwendung von polyetherestern zum rotationsformen
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
ATE443262T1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
MXPA06013176A (es) Dominios semejantes al factor de crecimiento epidermico de mucina 3.
ATE463562T1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
DE602005013805D1 (de) Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen
DE60218848D1 (de) Verfahren zur trennung und/oder zum nachweis und/oder zur identifizierung und/oder zur quantifizierung von prionproteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1378753

Country of ref document: EP

REN Ceased due to non-payment of the annual fee